ArticleBMC cancer2021

Patients with low nicotinamide N-methyltransferase expression benefit significantly from bevacizumab treatment in ovarian cancer.

Jun Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.